Document Detail

Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data.
MedLine Citation:
PMID:  23290599     Owner:  NLM     Status:  In-Data-Review    
Pulmonary hypertension (PH) in sarcoidosis is associated with bad outcomes. Although there is interest in using pulmonary vasodilators (PVs) for PH in sarcoidosis, there are few data to support their use. In this study, a retrospective review of a cohort of patients with PH and sarcoidosis was conducted, focusing on those treated with PVs, and a meta-analysis of published reports indexed in MEDLINE was performed. Twenty-four patients were found. The rate of mortality or transplantation rate was 41.2%. Median survival without transplantation was 5.3 years. More patients who died or underwent transplantation during follow-up had moderate or severe lung fibrosis (66.7% vs 15.4%), had right ventricular dysfunction (80% vs 7.7%), and were in World Health Organization class IV (66.7% vs 30.8%). Body surface areas were lower in patients with events, as was cardiac output. Mortality was not different between patients treated with PVs and those not treated (54.5% vs 38.5%, p = 0.44) despite the treated patients' having more right ventricular dysfunction and worse hemodynamics. In a Cox regression survival model, lower body surface area, right ventricular dysfunction, and the presence of moderate or severe lung fibrosis were predictors of worse outcomes, but not treatment with PVs. PV-treated patients (n = 11) showed improved 6-minute walk distances and decreased N-terminal pro-B-type natriuretic peptide levels during follow-up. There was a trend toward improvement in hemodynamic profile. Four studies plus the data from this study were included in the meta-analysis. Six-minute walk distance improved by 30.64 m after treatment. Hemodynamics improved, with a reduction in mean pulmonary arterial pressure of 8.03 mm Hg and a decrease in pulmonary vascular resistance of 4.23 Wood units. In conclusion, PH in sarcoidosis is associated with adverse outcomes, particularly when accompanied by right ventricular dysfunction and/or moderate or severe lung fibrosis. Treating selected patients can improve hemodynamics and functional parameters.
David Dobarro; Benjamin Emmanuel Schreiber; Clive Handler; Huw Beynon; Christopher P Denton; John Gerard Coghlan
Related Documents :
25015849 - Direct and indirect assessments of activities of daily living in behavioral variant fro...
23506859 - Coagulation in liver disease: a guide for the clinician.
24387169 - The expression of chemokine receptor cxcr3: relevance to disease activity of rheumatoid...
24096989 - Detection of acquired hemoglobinopathy in children with hematological malignancies at d...
22959399 - Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease.
23029349 - Cobalamin related parameters and disease patterns in patients with increased serum coba...
10852419 - Peripheral blood eosinophilia in association with sarcoidosis.
2433939 - Pancreatitis in kawasaki disease.
10466989 - Cerebral ischemic disease and morphometric analyses of carotid plaques.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  111     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  278-85     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2013. Published by Elsevier Inc.
National Pulmonary Hypertension Service, Royal Free Hospital, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blin...
Next Document:  NeuPAT: an intranet database supporting translational research in neuroblastic tumors.